Clinical Trial

Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.
Trial Details
NCT Number NCT07056790
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Prostate CA
Enrollment 40 participants
Start Date 2025-05-15
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-07-09